AddedRisk Factors
Under the terms of the Servier License Agreement, we have limited ability to influence and control Servier’s commercialization efforts for darovasertib. If Servier does not perform in conformance with the terms and conditions of the Servier License Agreement, the commercialization of darovasertib in territories outside the United States could be adversely impacted. Any legal or equitable remedies that we may obtain in the event of Servier’s breach of the Servier License Agreement may not adequately compensate us for the losses caused by Servier.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedRisk Factors
Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates or impair our competitive position. As the biotechnology industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedRisk Factors
As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedRisk Factors
The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of any product candidate that we commercialize.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RemovedRisk Factors
•expenditures that we may incur to acquire, develop or commercialize additional products and technologies;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
In connection with the GSK Collaboration Agreement, if GSK terminates any development program under its collaborations with us, whether as a result of our inability to meet milestones or otherwise, any potential revenue from those collaborations will be significantly reduced or non-existent, and our results of operations and financial condition will be materially and adversely affected.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have invested a significant portion of our time and financial resources in the development of multiple product candidates that are included in our strategic partnership and collaboration with GSK, under the GSK Collaboration Agreement entered into on June 15, 2020, or the GSK Collaboration Agreement. The programs currently included in the GSK Collaboration Agreement are the Pol Theta and WRN programs.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
Under the GSK Collaboration Agreement, we will be eligible to receive from GSK future development and regulatory milestones of up to $475.0 million for the Pol Theta and $475.0 million for the WRN product, and commercial milestones of up to $475.0 million, with respect to the Pol Theta and WRN product. Additionally, we are entitled to receive 50% of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. We are entitled to receive tiered royalties on global net sales of Pol Theta products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. We have a right to opt-out of the 50% U.S. net profit share and corresponding development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with potential positive economic adjustments based on the stage of the WRN program, as applicable, at the time of opt-out. There is no guarantee that we will be able to successfully continue to advance the Pol Theta and WRN programs and receive regulatory filing milestone payments related to any Pol Theta or WRN product. GSK may terminate the entire GSK Collaboration Agreement or any collaboration program on a target-by-target basis for any or no reason upon written notice to us after expiration of a defined notice period. The GSK Collaboration Agreement or any program under the GSK Collaboration Agreement may also be terminated by either party for the other party’s insolvency or certain uncured breaches. We may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain of our patents. Depending on the timing of any such termination we may not be entitled to receive the option exercise fees, or potential milestone payments, as these payments terminate with termination of the GSK Collaboration Agreement.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
If GSK terminates its rights and obligations with respect to a program or the entire GSK Collaboration Agreement, then depending on the timing of such event:
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the development of our product candidates subject to the GSK Collaboration Agreement may be terminated or significantly delayed;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates that were previously funded by GSK;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the GSK Collaboration Agreement, including the reimbursement of third parties; and
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•in order to fund further development and commercialization, we may need to seek out and establish alternative collaboration arrangements with third-party collaboration partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
but there is a tiered system extending the grace period for many in vitro diagnostic medical devices (depending on their risk classification) before they have to be fully compliant with the Regulation.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
while our precision medicine target and biomarker discovery platform and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded biopharmaceutical, biotechnological and oncology therapeutics companies, as well as universities and other research institutions.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
For BCG034, we are not aware of any other companies developing bispecific ADCs targeting both B7-H3 and PTK7; however, many companies are developing mono-antigen ADCs targeting either B7-H3 or PTK7. Merck and Hansoh are both
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedRisk Factors
If these bills the foreign CROs and CMOs we rely on become law, subject to trade restrictions, sanctions, increased tariffs or similar laws are passed, they would other regulatory requirements by the U.S. government (including designation as a BCC under the BIOSECURE Act), or if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the United States and China, it may have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology “biotechnology companies “of of concern” without losing the ability to contract with, or otherwise receive funding from, the U.S. government.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations and prospects.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result of our ceasing to be an emerging growth company and being deemed a “large accelerated filer” as of January 1, 2024, commencing with our Annual Report on Form 10-K for the year ending December 31, 2023, Additionally, our independent registered public accounting firm is required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to raise additional funds will depend on financial, economic and other factors, including the ongoing effects geopolitical conflicts, health outbreaks, and/or banking sector volatility, and any worsening of the COVID-19 pandemic, the Ukraine-Russia conflict, the Israel-Hamas conflict, global business and closure of or liquidity issues at financial institutions, economic environment, many of which are beyond our control.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidates or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, Immunocore is developing and commercializing has commercialized Tebentafusp, also known under its branded name as Kimmtrak, for the treatment of adult patients with HLA-A*02:01-positive HLA*A2(+), unresectable or MUM. iOnctura has initiated a Phase 2 trial for Roginolisib, an allosteric PI3K delta inhibitor, in 2L+ MUM. metastatic UM.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
CMS has published the negotiated prices for the initial ten drugs, which went into effect in 2026, and the subsequent 15 drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation, 2027, although the drug price negotiation program is currently subject to legal challenges.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, certain of our product candidates may be co-administered with third-party approved or experimental therapies, therapies in our clinical trials, such as darovasertib with crizotinib in the combination arms of our Phase 1/2 clinical trial or IDE397 with PRMT5 inhibitors in the combination arms of our Phase 1/2 clinical trial. inhibitors.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedRisk Factors
The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights and products by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In the future, we may also become dependent on other product candidates that we may develop or acquire; however, given the current stages of development for most of our product candidates, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to support approval for commercialization.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Some adverse effects of our product candidates will may not be uncovered until a significantly larger number of patients are exposed to the product candidate.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
We are a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs), for molecularly defined solid tumor indications. Our clinical development strategy is to evaluate our product candidates in rational combinations, where appropriate, and earlier in the course of disease in the adjuvant and neoadjuvant settings, which we believe has the potential to maximize their impact. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
Our current clinical pipeline consists of nine potential first-in-class product candidates across four clinical focus areas, as described below.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
Darovasertib is an oral, potent and selective small molecule inhibitor of protein kinase C (PKC) and our most advanced clinical program. We are developing darovasertib for uveal melanoma (UM), a rare, aggressive form of ocular cancer in both the metastatic and pre-metastatic settings of UM, as described below.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•Metastatic UM (mUM). We are evaluating darovasertib in combination with crizotinib, Pfizer’s oral c-MET inhibitor, in a potentially registration-enabling, Phase 2/3 trial (OptimUM-02) for human leukocyte antigen-A*02:01 negative (HLA*A2(-)), patients with first line (1L) mUM. We expect to report topline data, including progression free survival (PFS) data, from this trial in the first quarter of 2026. The data from OptimUM-02 may enable an accelerated approval filing in the United States. In December 2025, we completed full enrollment of 437 patients in OptimUM-02, and plan to submit overall survival (OS) data from these patients, when available, to support a full approval filing in this indication.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
We are also evaluating the combination of darovasertib and crizotinib in HLA*A2:01 positive (HLA*A2(+)), mUM patients in our ongoing, single-arm Phase 2 OptimUM-01 trial. We expect to complete enrollment of approximately 100 patients in this trial by the second quarter of 2026 with data used to support a potential future submission to the FDA to expand the labeled use for darovasertib and/or a national comprehensive cancer network (NCCN) compendia listing to enable use of the combination in these patients.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•Neoadjuvant UM. We are also evaluating darovasertib as a monotherapy in the neoadjuvant setting of primary UM, where the goal of treatment is to prevent enucleation (surgical eye removal), preserve vision prior to and post-plaque brachytherapy and potentially delay or prevent progression to metastatic disease. In 2025, we initiated a randomized Phase 3 trial of darovasertib in the neoadjuvant setting (OptimUM-10), which will enroll approximately 450 patients across two cohorts of plaque brachytherapy-eligible (PB) and enucleation-eligible (EN) patients. We plan to complete enrollment in this trial by the first half of 2027.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•Adjuvant UM. We plan to initiate a global Phase 3 combination trial (OptimUM-11) of darovasertib and crizotinib in the adjuvant setting of primary UM in the first half of 2026. The trial is expected to enroll approximately 450 patients with high to medium-high risk of metastasis, randomized 1:1 to the combination of darovasertib and crizotinib or placebo. The primary endpoint of this trial is relapse-free survival (RFS).
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
In August 2025, we entered into an exclusive license agreement with Les Laboratoires Servier (Servier), for the development and commercialization of darovasertib outside of the United States. We received an upfront payment of $210.0 million and are eligible to receive up to $320.0 million in milestone payments, clinical trial cost sharing and clinical trial cost reimbursement, as well as double-digit royalties on net sales in all territories outside of the United States.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•IDE849 is a potential first-in-class, DLL3 TOP1 ADC being evaluated by our partner, Hengrui Pharma, in a multi-site, open label Phase 1 clinical trial in China in patients with small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC). We are currently conducting a global Phase 1 trial of IDE849 in SCLC, with the goal of initiating a monotherapy registrational trial in the second line/refractory setting (2L+) of SCLC and/or NEC by the end of 2026.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•IDE034 is a potential first-in-class, B7H3/PTK7 bispecific TOP1 ADC. We received investigational new drug (IND) clearance from the FDA in the fourth quarter of 2025 and expect to achieve first-patient-in (FPI) in our Phase 1 dose escalation trial in the first quarter of 2026. Dosing of the first patient with IDE034 will trigger a $5.0 million milestone payment to Biocytogen, pursuant to our Option and License Agreement.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•IDE161 is a potential first-in-class, oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor in a Phase 1 dose optimization trial to inform future combination studies with IDE849 and other TOP1-based ADCs where PARG inhibition may synergize with the payload to deepen responses. We plan to initiate a Phase 1 clinical combination trial of IDE161 with IDE849 in SCLC, NEC, and potentially other DLL3-overexpressing solid tumors in the second quarter of 2026. We may also evaluate clinical combinations of IDE161 with IDE034 (B7H3/PTK7) and potentially other TOP1 ADCs in collaboration with third parties.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
AddedMD&A
•IDE705 is a potential first-in-class, oral small molecule inhibitor of the helicase domain of Pol Theta that had been in a Phase 1 combination trial with niraparib, GSK’s small molecule inhibitor of PARP, in patients with BRCA+ or other HRD-positive tumors. In December 2025, GSK notified us of its intention to terminate the Agreement, which will be effective March 9, 2026. We plan to begin preclinical studies evaluating the potential of IDE705 to enhance the efficacy of TOP1 ADCs in solid tumors, as we are doing with IDE161, within our focus area of ADC/DDR combinations.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RemovedMD&A
We are a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are most likely to benefit from these targeted therapies. Our small molecule drug discovery expertise includes discovery and development of small molecule therapeutics. We are applying these capabilities and approach to develop a robust pipeline in precision medicine oncology. Our clinical pipeline includes six potential first-in-class clinical-stage product candidates – darovasertib (PKC), IDE397 (MAT2A), IDE849(DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). We own or control all commercial rights of three of these product candidates: darovasertib, IDE397, and IDE161, and own or control all commercial rights outside of greater China for IDE849. We are also advancing several development candidates, including IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor for which we are targeting an investigational new drug, or IND, filing in mid-year 2025; IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload bispecific antibody drug conjugate, or BsADC, program for which we are targeting an IND filing in the second half of 2025; and IDE251, a potential first-in-class KAT6/7 dual inhibitor program for which we are targeting an IND filing in the second half of 2025. We also have multiple earlier-stage preclinical programs. We have established selective, value-accretive collaborations with leading pharmaceutical companies to support our clinical development activities.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
Darovasertib (IDE196) is our most advanced clinical-stage product candidate, which we in-licensed from Novartis. Darovasertib is a potent, selective small molecule inhibitor of protein kinase C, or PKC, which we are developing for genetically-defined cancers having GNAQ or GNA11 gene mutations. PKC is a protein kinase that functions downstream of the GTPases GNAQ and GNA11.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We have enrolled over 230 patients as of February 7, 2025, and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002. The purpose of the clinical trial is to evaluate darovasertib in combination with crizotinib, Pfizer’s investigational cMET inhibitor, in patients having metastatic uveal melanoma, or MUM, with human leukocyte antigen-, or HLA-A*02:01 negative, or HLA-A2(-), serotype, as part of the second Clinical Trial Collaboration and Supply Agreement, or Second Pfizer Agreement, with Pfizer.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
In December 2024, we announced the recommendation of a move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line, or 1L setting in patients with HLA-A2(-) MUM.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We are enrolling additional HLA-A*02:01 positive, or HLA-A2(+), patients as an independent clinical strategy to address HLA-A2(+) MUM patients, in our ongoing Phase 2 clinical trial, designated as IDE196-001.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We are targeting a median overall survival, or OS, readout from our Phase 2 clinical trial, designated as IDE196-001, in approximately 40 1L MUM patients in 2025.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We have enrolled 95 patients as of December 31, 2024, in our Phase 2 clinical trial, designated as IDE196-009, evaluating darovasertib as single-agent neoadjuvant and adjuvant therapy in patients having primary uveal melanoma, or UM, with ongoing enrollment and multiple clinical sites open. We are targeting a clinical data update in over 75 patients and regulatory update(s) in in the first half of 2025, including vision data in plaque brachytherapy patients.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
In September 2024, we announced interim clinical data from the ongoing Phase 2 Company-sponsored trial and provided a regulatory update on a potential Phase 3 registration-enabling clinical trial in neoadjuvant UM patients based on a Type C meeting held with the U.S. Food and Drug Administration, or FDA. Based on the FDA meeting, we currently project approximately 400 patients will be randomized for treatment with darovasertib in the treatment arm or the control arm, with potential modifications pending further feedback from the FDA. We are currently finalizing the trial protocol for neoadjuvant UM and are targeting to initiate the study in the first half of 2025.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We are also supporting evaluation of darovasertib as single-agent neoadjuvant and adjuvant therapy in primary UM in an ongoing investigator-sponsored clinical trial, or IST, captioned as “Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma,” or NADOM, led by St. Vincent’s Hospital in Sydney with the participation of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
In June 2024, we announced interim clinical data from the ongoing investigator-sponsored Phase 2 trial of darovasertib as neoadjuvant/adjuvant treatment in UM, which was included in an oral presentation at the American Society of Clinical Oncology, or ASCO, 2024 Annual Meeting, and preliminary clinical data from our Phase 2 trial of darovasertib for neoadjuvant UM.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We own or control all commercial rights in our darovasertib program in UM, including in MUM and in primary UM, subject to certain economic obligations pursuant to our exclusive, worldwide license to darovasertib with Novartis.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
IDE397, our small molecule methionine adenosyltransferase 2a, or MAT2A, inhibitor, is being evaluated in a Phase 1/2 clinical trial. We have selected a move-forward Phase 2 expansion dose for IDE397 monotherapy, based on adverse event, or AE, profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1. We are enrolling patients with an initial focus in MTAP-deletion urothelial cancer, or UC, and non-small cell lung cancer, or NSCLC.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedMD&A
The net change in our operating assets and liabilities consisted primarily of cash inflows resulting from $8.3 a $2.6 million increase in lease liabilities, $2.7 million increase in accounts payable and $10.8 $10.4 million increase in accrued and other liabilities due to CRO fees paid to CROs, CMOs and consultants in support of research and manufacturing activities, partially offset by cash outflows of $6.2 resulting from a $7.8 million increase in prepaid and other assets and $1.4 $6.0 million increase in lease liabilities. contract assets related to the Servier License Agreement.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in research and development expenses was primarily due to $75.0 million upfront payment under the Hengrui Pharma License Agreement for IDE849, $6.5 million in upfront and option exercise fees under the Biocytogen Option and License Agreement for IDE034, increases of $64.1 $74.1 million in fees paid to CROs, CMOs and consultants related to the advancement of our lead product candidates through preclinical and clinical studies, $15.6 $12.7 million in personnel-related expenses, including salaries, benefits and stock-based compensation, to support our growth, and $4.0 $8.2 million in costs for laboratory supplies, facilities and information technology costs to support our research and development programs.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in provided by investing activities was $502.6 $70.0 million for the year ended December 31, 2024, 2025, which consisted primarily of $1.2 $680.2 million provided by maturities of marketable securities, offset by $607.9 billion used to purchase marketable securities and $3.9 $2.4 million used to purchase property and equipment, partially offset by $692.6 million provided by maturities of marketable securities. equipment.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
See the section titled “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” in For more detail on our critical accounting policies, refer to Note 2 to our the financial statements included appearing elsewhere in this Annual Report on Form 10-K for additional information. 10-K.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by financing activities was $677.6 $29.8 million for the year ended December 31, 2024, 2025, which consisted primarily of $274.4 million of net proceeds from our follow-on offering, $9.4 million of proceeds from issuance of pre-funded warrants, $379.9 $24.9 million of proceeds from ATM offering, $12.5 $3.4 million of proceeds from exercise of common stock options and $1.4 $1.5 million of proceeds from ESPP purchase. purchases.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
See the section titled “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” in Note 2 to our the financial statements included elsewhere in this Annual Report on Form 10-K for additional information. a description of recent accounting pronouncements that are applicable to our business and may potentially have an impact on our financial position and results of operations.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Darovasertib $ 98,071 $ 55,335 $ 25,829 IDE397(2) IDE397 14,662 16,629 11,985 IDE161 7,598 9,743 7,104 IDE849 11,457 75,000 Personnel related and stock-based compensation 67,192 54,543 38,948 Other research and development expenses (3): 158,423 45,642 expenses(2) 115,724 83,423 Total research and development expenses $ 314,704 $ 294,673 $ 129,508
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Our revenue consists exclusively of collaboration revenue under the Servier License Agreement for the year ended December 31, 2025 and the GSK Collaboration Agreement, Agreement for the year ended December 31, 2024, including amounts that are recognized related to previously received upfront payments, development and regulatory milestone payments and amounts due and payable to us for research and development services.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Our non-cash charges consisted of $34.7 million in stock-based compensation, $2.4 million in depreciation and $1.4 million of the amortization of right of use assets, partially offset by $23.2 million accretion of discounts on marketable securities.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
Interest income increased decreased by $31.0 $6.9 million, or 145%, 13%, during the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, 2024, primarily due to higher lower interest rates and investment balances. rates.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, pursuant to the January 2024 Sales Agreement, 2025, we sold an aggregate of 4,066,866 984,000 shares of our common stock for aggregate net proceeds of $164.0 $25.0 million at a weighted average sales price of approximately $41.28 $26.00 per share under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new
Quiet changesMD&A
We have primarily incurred net losses since our inception.
Read it in 10-K Feb 17, 2026 at sec.govopen_in_new